Philippine National Drug Formulary

More documents

Recommendations

Info

PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 Jose M. Acuin, MD, MSc Alejandro C. Baroque II, MD Bu C. Castro, MD NATIONAL FORMULARY COMMITTEE Dina V. Diaz, MD Mario R. Festin, MD, MS, MHPEd Estrella B. Paje-Villar, MD, DTM & H Chairperson BFAD Representative Alma L. Jimenez, MD Marieta B. de Luna, MD Nelia P. Cortes-Maramba, MD Yolanda R. Robles, PhD Pharm Isidro C. Sia, MD SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii
Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta. Cruz, 1003 Manila TL: 743-83-01; DL: 711-9501; Fax: 743-1829; 743-1829; 743-1786 M E S S A G E Republic Act 9502 , also known as the Universally Accessible Cheaper and Quality Medicines Act of 2008, and its Implementing Rules and Regulations (IRR) have been signed. As stated in IRR Rule #36, "All government agencies, including local government units, shall procure drugs and medicines within the Philippine National Drug Formulary (PNDF) current edition in accordance with Republic Act 9184 and any other pertinent procurement reforms". Likewise, pursuant to Executive Order 49, that "all government entities concerned are mandated to use the current PNDF (Volume I) as the basis for procurement of drug products". The National Drug Policy-Pharmaceutical Management Unit 50 of the Department of Health (DOH) proudly presents the 7th edition of the PNDF, Volume I, Essential Medicines List. The PNDF is a dynamic list which is regularly reviewed and updated to make it truly relevant to the health needs of the majority of the population. In behalf of the DOH, we would like to thank and recognize the dedication and support of all members of the National Formulary Committee and the National Drug Information Center, and various resource persons in the preparation and completion of this edition. FRANCISCO T. DUQUE III, M.D., M.Sc. Secretary of Health v
Page 1 and 2: DEPARTMENT OF HEALTH National Drug
Page 3: All rights reserved 2008 The Nation
Page 7 and 8: THE PHILIPPINE NATIONAL DRUG POLICY
Page 9 and 10: P R E F A C E to the 7th edition Th
Page 11 and 12: TABLE OF CONTENTS PART I PART II Th
Page 13: Appendix Y — Republic Act No. 950
Page 16 and 17: 2.2 ANTI‐OSTEOPOROSIS MEDICINES 2
Page 18 and 19: Cardiac glycoside Angiotensin‐con
Page 20 and 21: 13.10 GASTROKINETICS (PROKINETICS)
Page 22: 20 EAR, NOSE AND THROAT PREPARATION
Page 25 and 26: g — Gram HSA-free — Human Serum
Page 27 and 28: CORE LIST Complementary List Route
Page 55 and 56:
CORE LIST Complementary List Route
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
16.1.2 Parenteral CORE LIST Complem
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
18.3 ANTISEPTICS CORE LIST Compleme
Page 127 and 128:
18.6 EMOLLIENT CORE LIST Complement
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 142 and 143:
APPENDIX A PHILIPPINE NATIONAL DRUG
Page 144 and 145:
APPENDIX B 5. Calcipotriol + betame
Page 146 and 147:
APPENDIX C 15. Clofazimine Oral: 50
Page 148 and 149:
43. Human menopausal gonadotrophin
Page 150 and 151:
APPENDIX C 69. Ritonavir Oral: 100
Page 152 and 153:
APPENDIX D NEW DRUGS UNDER MONITORE
Page 154 and 155:
APPENDIX E MEDICINES IN PNDF WITH A
Page 156 and 157:
APPENDIX F 77. Human Menopausal Gon
Page 158 and 159:
79. Lidocaine 108. Pralidoxime chlo
Page 160 and 161:
APPENDIX I LIST B MEDICINES List B
Page 162 and 163:
APPENDIX J MEDICINAL PLANT PRODUCTS
Page 164 and 165:
1.4 APPENDIX K * Per DDB Resolution
Page 166 and 167:
APPENDIX L MEDICAL DEVICES / SUPPLI
Page 168 and 169:
7. Evaluate the additional inputs f
Page 170 and 171:
9. 10. 8.5 the drugs that are easy
Page 172 and 173:
APPENDIX P CRITERIA FOR INCLUSION A
Page 174 and 175:
APPENDIX Q ROSALINDA CASTAÑEDA, MD
Page 176 and 177:
APPENDIX Q CECILIA MONTALBAN, MD UP
Page 178 and 179:
APPENDIX Q AILEEN DUALAN, MD BIENVE
Page 180 and 181:
APPENDIX R Sec. 1 Title. ‐ This A
Page 182 and 183:
APPENDIX R Sec. 6 Who Shall Use Gen
Page 184 and 185:
(C) APPENDIX R the discretion of th
Page 186 and 187:
. The following procedures shall be
Page 188 and 189:
APPENDIX T ADMINISTRATIVE ORDER NO.
Page 190 and 191:
APPENDIX T sanitaria. At the Region
Page 192 and 193:
11.2 11.3 11.4 12. Prescribing and
Page 194 and 195:
APPENDIX U ADMINISTRATIVE ORDER NO.
Page 196 and 197:
APPENDIX U 2.3.2 The special DDB pr
Page 198 and 199:
Section 7 TIMETABLE OF IMPLEMENTATI
Page 200 and 201:
Section 3 In addition to the guidel
Page 202 and 203:
APPENDIX V 5.1 Imposing a particula
Page 204 and 205:
APPENDIX W April 23, 1990 ADMINISTR
Page 206 and 207:
APPENDIX X 3. 4. 5. Auditors/heads
Page 208 and 209:
ANNEX B PART II: REVIEW OF NEW DRUG
Page 210 and 211:
A ANNEX D ANNOTATIONS Some drugs of
Page 212 and 213:
APPENDIX Y (b) (c) (d) (e) (f) (g)
Page 214 and 215:
APPENDIX Y prior art, it is not obv
Page 216 and 217:
"(f) "(g) APPENDIX Y The right hold
Page 218 and 219:
"(b) "(c) "(d) APPENDIX Y SECTION 1
Page 220 and 221:
(A) (i) (ii) (iii) (iv) (a) (b) (c)
Page 222 and 223:
(a) (b) (c) (d) (e) (f) APPENDIX Y
Page 224 and 225:
APPENDIX Y SECTION 28. Role of the
Page 226 and 227:
“SEC. 6. Who Shall Use Generic Te
Page 228 and 229:
(d) APPENDIX Y and suspension of hi
Page 230 and 231:
APPENDIX Y SECTION 49. Effectivity
Page 232 and 233:
APPENDIX Z Rule 4. Coverage. Unless
Page 234 and 235:
(o) APPENDIX Z “Immediate contain
Page 236 and 237:
(b) (c) (d) (e) (f) APPENDIX Z whic
Page 238 and 239:
(vi) (a) APPENDIX Z in accordance w
Page 240 and 241:
APPENDIX Z Section 2. Civil Action.
Page 242 and 243:
(d) (e) APPENDIX Z taking into acco
Page 244 and 245:
APPENDIX Z (a) (b) (c) Submission o
Page 246 and 247:
APPENDIX Z Provided, that adequate
Page 248 and 249:
APPENDIX Z CHAPTER III PARALLEL IMP
Page 250 and 251:
APPENDIX Z Rule 25. Other Powers Ne
Page 252 and 253:
APPENDIX Z (c) (d) (e) (f) (g) Drug
Page 254 and 255:
APPENDIX Z principles of administra
Page 256 and 257:
(3) (4) (5) Consignment procedures
Page 258 and 259:
APPENDIX Z Rule 44. Who Shall Use G
Page 260 and 261:
APPENDIX Z markets, convenience sto
Page 262 and 263:
APPENDIX Z Rule 66. Role of the Dep
Page 264 and 265:
APPENDIX Z e. f. 5th and succeeding
Page 266 and 267:
Rule 86. Amendments. CHAPTER XV MIS
Page 268 and 269:
APPENDIX Z (i) Only the amount nece
Page 270 and 271:
DEPARTMENT OF HEALTH National Drug
Page 272 and 273:
MEASUREMENTS : 1 grain = 60 mg 1/2
Page 274 and 275:
1 — Occurrence of Target Conditio
Page 276 and 277:
Ferrous fumarate — Ferrous glucon
Page 278 and 279:
Citrate — Glucose anhydrous — T
Page 280 and 281:
CATEGORY B : PRIMARY CARE MEDICINES
Page 282 and 283:
250 mg/5 mL granules/powder for syr
Page 284 and 285:
7. ANTIPEPTIC ULCER DISEASE V E L F
Page 286 and 287:
Furosemide Oral: 40 mg tablet (B) I
Page 288 and 289:
Medroxyprogesterone Inj.: 50 mg/mL,
Page 290 and 291:
Metronidazole Nifedipine Nitrofuran
Page 292 and 293:
LIST OF DOH RETAINED HOSPITALS Cent
Page 294 and 295:
CHD IX - Zamboanga Peninsula Basila
Page 296 and 297:
Lung Center of the Philippines Quez
Page 298 and 299:
Ampicillin + Sulbactam Anti‐D Imm
Page 300 and 301:
Cefadroxil Cefalexin Cefazolin Cefe
Page 302 and 303:
Didanosine Diethylcarbamazine Digox
Page 304 and 305:
Fluocinonide Fluorescein Fluoride F
Page 306 and 307:
Idarubicin Ifosfamide Imatinib Imid
Page 308 and 309:
Mannitol Mebendazole Mebeverine Mec
Page 310 and 311:
Oral Rehydration Salts (ORS 75‐re
Page 312 and 313:
Salicylic Acid Sambong Saquinavir S
Page 314 and 315:
Valsartan + Hydrochlorothiazide Van
show all

Philippine National Drug Formulary

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?